<SEC-DOCUMENT>0000886163-24-000029.txt : 20240507
<SEC-HEADER>0000886163-24-000029.hdr.sgml : 20240507
<ACCEPTANCE-DATETIME>20240507160328
ACCESSION NUMBER:		0000886163-24-000029
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240507
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240507
DATE AS OF CHANGE:		20240507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIGAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000886163
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				770160744
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33093
		FILM NUMBER:		24921698

	BUSINESS ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-550-7500

	MAIL ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lgnd-20240507.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:e19915be-7a7d-4a0a-a910-a91be24fe392,g:99d91fad-30df-4421-95f8-e2e75b059fe5,d:c20cedd66b074a67b5e833a7827ed6a8-->
<html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lgnd-20240507</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0000886163</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-22">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lgnd-20240507.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-07</xbrli:startDate><xbrli:endDate>2024-05-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic20cedd66b074a67b5e833a7827ed6a8_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:173%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:173%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:173%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:173%">______________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:173%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:173%">______________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:173%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:173%">Pursuant to Section 13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:173%">Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May 7, 2024</ix:nonNumeric> </span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:173%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">LIGAND PHARMACEUTICALS INC</ix:nonNumeric>ORPORATED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">     </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.538%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-33093</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">77-0160744</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Identification No.)</span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">555 Heritage Drive, Suite 200</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Jupiter</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Florida</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">33458</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">858</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">550-7500</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%">N/A</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span><br/></span></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;&#160;&#160;&#160;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Ac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">t:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"/><td style="width:37.797%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.610%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">LGND</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic20cedd66b074a67b5e833a7827ed6a8_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">On May 7, 2024, Ligand Pharmaceuticals Incorporated (the &#8220;Company&#8221;) issued a press release announcing its financial results for the three months ended March 31, 2024. A copy of this press release is furnished herewith as Exhibit 99.1 to this report.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-bottom:19pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Exhibits.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:13.323%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.477%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-right:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-1.5pt;text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q12024earningsrelease_ex991.htm">99.1</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:-3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Press release dated May 7, 2024.</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:20pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.993%"><tr><td style="width:1.0%"/><td style="width:40.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:56.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIGAND PHARMACEUTICALS INCORPORATED</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 7, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:38.25pt;padding-right:2.25pt;text-indent:-33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Andrew Reardon        </span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:38.25pt;padding-right:2.25pt;text-indent:-33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:    Andrew Reardon</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:38.25pt;padding-right:2.25pt;text-indent:-33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:   Chief Legal Officer and Secretary </span></div></td></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q12024earningsrelease_ex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i1d81e92f90b140149f4881ed9e9342a8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font><br></font></div><div id="i1d81e92f90b140149f4881ed9e9342a8_45"></div><div style="text-align:center"><img alt="newligandlogo.jpg" src="newligandlogo.jpg" style="height:83px;margin-bottom:5pt;vertical-align:text-bottom;width:240px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Ligand Reports First Quarter 2024 Financial Results</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Conference Call Begins at 4&#58;30 p.m. Eastern Time Today</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">JUPITER, Fla., May 7, 2024 &#8211; Ligand Pharmaceuticals Incorporated (Nasdaq&#58; LGND)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4&#58;30 p.m. Eastern Time to discuss this announcement and answer questions.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;We are pleased to report another quarter of strong financial results driven by the performance of our commercial royalty portfolio.  Simultaneously, we continue to build our portfolio of development stage royalty assets to deliver future growth,&#8221; said Todd Davis, CEO of Ligand. &#8220;We continue to originate a robust pipeline of royalty opportunities with our proactive business development efforts.  This is evidenced by our most recent royalty financing agreement with Agenus which will add several new late stage oncology assets to our portfolio. As we look ahead to the near term, we have several important catalysts in our existing portfolio in 2024. This includes Verona Pharma&#8217;s ensifentrine and Merck&#8217;s V116, both of which have been assigned PDUFA dates in June, top-line Phase 3 data on Takeda&#8217;s soticlestat, expected in the third quarter, and the commercial launch of ZELSUVMI&#174;, a much-needed treatment for molluscum contagiosum, in late 2024.&#8221;  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">First Quarter 2024 Financial Results</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total revenues and other income for the first quarter of 2024 were $31.0 million, compared with $44.0 million for the same period in 2023. Royalties for the first quarter of 2024 were $19.1 million, compared with $17.6 million for the same period in 2023, with the increase primarily attributable to Amgen&#8217;s (Nasdaq&#58; AMGN) Kyprolis, Jazz Pharmaceuticals' (Nasdaq&#58; JAZZ) RYLAZE, Merck and Co.&#8217;s (NYSE&#58; MRK) VAXNEUVANCE and Travere Therapeutics&#8217; (Nasdaq&#58; TVTX) FILSPARI, partially offset by a decline in CASI&#8217;s (Nasdaq&#58; CASI) EVOMELA. Captisol sales were $9.2 million for the first quarter of 2024, compared with $10.6 million for the same period in 2023, with the change due to the timing of customer orders. Contract revenue and other income was $2.7 million for the first quarter of 2024, compared with $15.7 million for the same period in 2023, with the difference driven by a $15.3 million milestone payment earned from Travere Therapeutics upon the FDA approval of FILSPARI in the prior year quarter. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cost of Captisol was $2.9 million for the first quarter of 2024, compared with $3.7 million for the same period in 2023, with the decrease due to lower total Captisol sales. Amortization of intangibles was $8.2 million for the first quarter of 2024, compared with $8.5 million for the same period in 2023. Research and development expense was $6.0 million for the first quarter of 2024, compared with $6.7 million for the same period in 2023. General and administrative expense was $11.0 million for the first quarter of 2024, compared with $10.9 million for the same period in 2023.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net income from continuing operations for the first quarter of 2024 was $86.1 million, or $4.75 per diluted share, compared with net income from continuing operations of $43.6 million, or $2.43 per diluted share, for the same period in 2023. The increase in net income from the prior year period is due primarily to realized gains from short-term investments associated with Viking Therapeutics (Nasdaq&#58; VKTX) stock of $60.0 million. Adjusted net income from continuing operations for the first quarter of 2024 was $69.7 million, or $3.84</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">per diluted share, compared to $39.9 million, or $2.28 per diluted share, for the same period in 2023. Excluding the impact of gains from sales of Viking Therapeutics stock, core adjusted net income from continuing operations was $21.8 million, or </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$1.20 per diluted share, compared with $23.4 million, or $1.33 per diluted share, for the same period in 2023. The decrease in core adjusted net income is driven by the $15.3 million milestone payment earned from Travere Therapeutics in the prior year quarter. See the table below for a reconciliation of net income from continuing operations to adjusted net income from continuing operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March 31, 2024, Ligand had cash, cash equivalents and short-term investments of $310.6 million. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2024 Financial Guidance </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ligand is reaffirming its 2024 financial guidance. The Company expects 2024 royalties ranging from $90 million to $95 million, sales of Captisol to range from $25 million to $27 million, and contract revenue ranging from $15 million to $20 million. These revenue components result in total revenue forecast of $130 million to $142 million. Ligand notes that with total revenue of $130 million to $142 million, core adjusted earnings per diluted share are expected to range from approximately $4.25 to $4.75.  This guidance excludes the $60 million gain from short-term investments on the sale of Viking Therapeutics stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">First Quarter and Recent 2024 Business Highlights</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On May 7, Ligand announced a $100 million royalty financing agreement with Agenus, Inc. Under the terms of the agreement, in exchange for an initial $75 million payment, Ligand will receive 18.75% of the royalties and 31.875% of the future milestones on six Agenus-partnered oncology programs including BMS-986442 (Bristol Myers Squibb), AGEN2373 (Gilead Sciences), INCAGN2385 and INCAGN2390 (Incyte), MK-4830 (Merck), and UGN-301 (UroGen Pharma). Ligand will also receive a 2.625% royalty on future global net sales of Agenus&#8217; novel immuno-oncology botensilimab in combination with balstilimab (&#8220;BOT&#47;BAL&#8221;) program. Agenus&#8217; BOT&#47;BAL program received Fast Track Designation from the U.S. FDA in April 2023 for patients with metastatic, refractory colorectal cancer that is not MSI-H&#47;dMMR, who do not have liver metastases, and who failed first and second line standard of care treatments. The capital will support Agenus&#8217; upcoming Phase 3 BOT&#47;BAL colorectal cancer trial and other key commercialization activities. Ligand has an option to invest an additional $25 million to increase its economics on a pro rata basis for the additional investment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On April 3, Ligand announced the creation of Pelthos Therapeutics under the leadership of Scott Plesha as Chief Executive Officer. Pelthos is focused on the commercialization of innovative, safe, and efficacious therapeutic products for patients suffering from conditions with limited treatment options. ZELSUVMI&#8482; (berdazimer topical gel, 10.3%), its first product, is the first and only FDA-approved prescription medicine for the treatment of the highly transmissible molluscum contagiosum (molluscum) viral skin infection in adults and pediatric patients one year of age and older. It can be applied by patients, parents, or caregivers at home, outside of a physician's office, or other medical setting. ZELSUVMI received a Novel Drug designation from the U.S. FDA in January 2024 to treat molluscum viral skin infection. ZELSUVMI was developed using Pelthos' proprietary nitric oxide-based NITRICIL&#8482; technology platform. Commercial availability of ZELSUVMI in the United States is expected by late 2024. The rights to ZELSUVMI and all assets related to the NITRICIL technology platform were acquired from Novan, Inc. in September 2023. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Portfolio Updates</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">On April 24, Travere Therapeutics and CSL Vifor (ASX&#58; CSL), Travere&#8217;s commercial partner in Europe, gained European Commission conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with primary IgA nephropathy (IgAN). All member states of the EU, including Iceland, Liechtenstein, and Norway are included in the CMA.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The European Commission's decision follows the Committee for Medicinal Products for Human Use (CHMP)'s positive opinion in February 2024, based on results from the pivotal Phase 3 PROTECT study of FILSPARI in IgAN. The PROTECT study met its primary endpoint at the pre-specified interim analysis with statistical significance. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">On May 6, Travere Therapeutics announced the FDA granted Priority Review for its sNDA to convert FILSPARI&#174; (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S. with a PDUFA target action date of September 5, 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On April 24, Viking announced that in the first quarter this year they completed the 52-week biopsies for the Phase 2b VOYAGE study of VK2809 in biopsy-confirmed NASH and fibrosis.  As we've previously mentioned, the study successfully achieved its primary endpoint after 12 weeks of treatment and affirmed VK2809's potent effect on liver fat, along with its favorable tolerability and safety profile. Viking plans to report data on histologic changes assessed after 52 weeks of treatment later in the second quarter of 2024.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On April 15, Marinus Pharmaceuticals provided an update on the Phase 3 RAISE trial evaluating the safety and efficacy of IV ganaxolone in patients with refractory status epilepticus. The trial did not meet pre-defined stopping criteria at the interim analysis&#59; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected in the summer of 2024. Future development of IV ganaxolone in refractory status epilepticus will be assessed following review of the final RAISE results. Marinus remains blinded to the RAISE trial data.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Adjusted Financial Measures</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ligand reports adjusted net income and adjusted net income per diluted share in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.  The Company&#8217;s financial measures under GAAP include share-based compensation expense, amortization of debt-related costs, amortization related to acquisitions and intangible assets, changes in contingent liabilities, mark-to-market adjustments for amounts relating to its equity investments in public companies, excess tax benefit from share-based compensation, income tax effect of adjusted reconciling items and others that are listed in the itemized reconciliations between GAAP and adjusted financial measures included at the end of this press release. However, the Company does not provide reconciliations of such forward-looking adjusted measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for changes in contingent liabilities, changes in the market value of its investments in public companies, share-based compensation expense and the effects of any discrete income tax items.  Management has excluded the effects of these items in its adjusted measures to assist investors in analyzing and assessing the Company&#8217;s past and future core operating performance. Additionally, adjusted earnings per diluted share is a key component of the financial metrics utilized by the Company&#8217;s board of directors to measure, in part, management&#8217;s performance and determine significant elements of management&#8217;s compensation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Conference Call</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ligand management will host a conference call today beginning at 4&#58;30 p.m. Eastern Time (1&#58;30 p.m. Pacific Time) to discuss this announcement and answer questions.  To participate via telephone, please dial (800) 715-9871 using the conference ID 8755336. Callers outside the U.S. may dial 1-(646) 307-1963. To participate via live or replay webcast, a link is available at www.ligand.com.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Ligand Pharmaceuticals</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Its business model seeks to generate value for stockholders by creating a diversified portfolio of biopharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand&#8217;s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Its business model focuses on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing its technology to help partners discover and develop medicines. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate its revenue. Ligand&#8217;s Captisol&#174; platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances, licenses and other business relationships with the world&#8217;s leading biopharmaceutical companies including Amgen, Merck, </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International. For more information, please visit</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">at www.ligand.com. Follow Ligand on X  &#64;Ligand_LGND.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Captisol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Captisol was invented and initially developed by scientists in the laboratories of Dr. Valentino Stella, University Distinguished Professor at the University of Kansas' Higuchi Biosciences Center, for specific use in drug development and formulation. This unique technology has enabled several FDA-approved products, including Amgen's Kyprolis&#174;, Baxter's NEXTERONE, Acrotech Biopharma's EVOMELA&#174;, Sage Therapeutics' ZULRESSO&#174;, Gilead&#8217;s VEKLURY&#174;, and Merck's NOXAFIL&#174;. More information is available at www.captisol.com.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. Words such as &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; and &#8220;will,&#8221; and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding&#58; Ligand&#8217;s ability to expand its portfolio with life sciences royalty opportunities&#59; the timing of clinical and regulatory events of Ligand&#8217;s partners, including the expected commercial launch of Zelsuvmi by Pelthos Therapeutics&#59; the timing of the initiation or completion of preclinical studies and clinical trials by Ligand and its partners&#59; the timing of product launches by Ligand or its partners&#59; and guidance regarding the full-year 2024 financial results. Actual events or results may differ from Ligand's expectations due to risks and uncertainties inherent in Ligand&#8217;s business, including, without limitation&#58; Ligand relies on collaborative partners for milestone payments, royalties, materials revenue, contract payments and other revenue projections and may not receive expected revenue&#59; Ligand may not receive expected revenue from Captisol material sales&#59; Ligand and its partners may not be able to timely or successfully advance any product(s) in its internal or partnered pipeline or receive regulatory approval and there may not be a market for the product(s) even if successfully developed and approved&#59; Ligand may not achieve its guidance for 2024&#59; Ligand faces competition in acquiring royalties and locating suitable royalties to acquire&#59; Ligand may not be able to create future revenues and cash flows through the acquisition of royalties or by developing innovative therapeutics&#59; products under development by Ligand or its partners may not receive regulatory approval&#59; the total addressable market for our partners&#8217; products may be smaller than estimated&#59; Ligand faces competition with respect to its technology platforms which may demonstrate greater market acceptance or superiority&#59; Ligand is currently dependent on a single source sole supplier for Captisol and failures by such supplier may result in delays or inability to meet the Captisol demands of its partners&#59; Ligand&#8217;s partners may change their development focus and may not execute on their sales and marketing plans for marketed products for which Ligand has an economic interest&#59; Ligand&#8217;s and its partners&#8217; products may not be proved to be safe and efficacious and may not perform as expected and uncertainty regarding the commercial performance of such products&#59; Ligand or its partners may not be able to protect their intellectual property and patents covering certain products and technologies may be challenged or invalidated&#59; Ligand's partners may terminate any of its agreements or development or commercialization of any of its products&#59; Ligand and its partners may experience delays in the commencement, enrollment, completion or analysis of clinical testing for its product candidates, or significant issues regarding the adequacy of its clinical trial designs or the execution of its clinical trials, challenges, costs and charges associated with integrating acquisitions with Ligand&#8217;s existing businesses&#59; Ligand may not be able to successfully commercialize ZELSUVMI&#59; the potential impact of six partnered programs, including BMS-986442 (Bristol Myers Squibb), AGEN2373 (Gilead Sciences), INCAGN2385 and INCAGN2390 (Incyte), MK-4830 (Merck), and UGN-301 (UroGen Pharma)&#59; the trial and regulatory success of Agenus&#8217; upcoming Phase 3 trial of botensilimab in combination with balstilimab (&#8220;BOT&#47;BAL&#8221;) for patients with metastatic, refractory colorectal cancer that is not MSI-H&#47;dMMR and who do not have liver metastases&#59; Ligand may not be able to successfully implement its strategic growth plan and continue the development of its proprietary programs&#59; restrictions under Ligand's credit agreement may limit its flexibility in operating its business and a default under the agreement could result in a foreclosure of the collateral securing such obligations&#59; changes in </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">general economic conditions, including as a result of war, conflict or epidemic diseases and ongoing or future litigation could expose Ligand to significant liabilities and have a material adverse effect on the company. The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand's stock price. Additional information concerning these and other risk factors affecting Ligand can be found in prior press releases available at www.ligand.com as well as in Ligand's public periodic filings with the Securities and Exchange Commission available at www.sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release, including the possibility of additional license fees and milestone revenues we may receive. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Disclaimers and Trademarks</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The information in this press release regarding certain third-party products and programs, including ensifentrine, a Verona product candidate, V116, a Merck product candidate, Soticlestat, a Takeda product candidate, Kyprolis, an Amgen product, Rylaze, a Jazz Pharmaceuticals product, Vaxneuvance, a Merck product, FILSPARI, a Travere Therapeutics product, QTORIN, Evomela, a CASI product, and other programs described herein, comes from information publicly released by the owners of such products and programs. Ligand is not responsible for, and has no role in, the development of such products or programs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ligand owns or has rights to trademarks and copyrights that it uses in connection with the operation of its business including its corporate name, logos and websites. Other trademarks and copyrights appearing in this press release are the property of their respective owners. The trademarks Ligand owns include Ligand&#174;, Captisol&#174; and ZELSUVMI, a Novan product. Solely for convenience, some of the trademarks and copyrights referred to in this press release are listed without the &#174;, &#169; and &#8482; symbols, but Ligand will assert, to the fullest extent under applicable law, its rights to its trademarks and copyrights.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contacts&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ligand Pharmaceuticals Incorporated                                                            LifeSci Advisors </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mike Jeong                                                                                                     Bob Yedid</font></div><div style="text-align:justify"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">investors&#64;ligand.com                                                                                    bob&#64;lifesciadvisors.com</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(561) 214-4232</font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">                                                                                               </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(516) 428-8577 </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">           </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Twitter&#47; X&#58; &#64;Ligand_LGND                                                                   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Tables Follow&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Unaudited, in thousands, except per share amounts)</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.187%"><tr><td style="width:1.0%"></td><td style="width:64.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.895%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues and other income&#58;</font></td><td colspan="3" style="border-top:1pt solid #333333;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #333333;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Revenue from intangible royalty assets</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,357&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,154&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Income from financial royalty assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">738&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalties</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,095&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,647&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Captisol</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,212&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,622&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract revenue and other income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,671&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,710&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total revenues and other income</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,978&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,979&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating costs and expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of Captisol</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,882&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,717&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangibles</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,186&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,539&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,971&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,663&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,951&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,855&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total operating costs and expenses</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,990&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,774&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from operations</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,988&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,205&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain from short-term investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,772&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,533&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,879&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,195&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on derivative instruments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-operating income (expense), net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,388)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">603&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total other income, net</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,459&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,331&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income taxes from continuing operations</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113,447&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,536&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27,308)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,922)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income from continuing operations</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,139&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,614&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss from discontinued operations</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,665)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net  income&#58;</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,139&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,949&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net income from continuing operations per share</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.86&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.56&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net loss from discontinued operations per share</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.10)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net income per share</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.86&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.46&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares used in basic per share calculation</font></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,732&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,063&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted net income from continuing operations per share</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.43&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted net loss from discontinued operations per share</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted net income per share</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares used in diluted per share calculation</font></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,122&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,974&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(unaudited, in thousands)</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:51.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.008%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Cash, cash equivalents and short-term investments</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310,593&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,309&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Accounts receivable, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,435&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,917&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Inventory</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,337&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,969&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Income tax receivable</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,395&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Prepaid expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,182&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Other current assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,311&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,657&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">368,913&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237,429&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Deferred income taxes, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Goodwill and other identifiable intangible assets, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396,670&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402,976&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Long-term portion of financial royalty assets, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,710&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,291&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Property and equipment, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,135&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,607&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Operating lease right-of-use assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,028&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,062&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Financing lease right-of-use assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,219&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,393&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Equity method investment in Primrose Bio</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,469&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,595&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Other investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,500&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,726&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Other assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,225&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,923&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">913,869&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">787,216&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #333333;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #333333;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Accounts payable and accrued liabilities</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,323&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,894&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Income tax payable</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,138&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Current contingent liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Current operating lease liabilities </font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Current finance lease liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Current deferred revenue</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,227&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,222&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current liabilities</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,818&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,782&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Long-term contingent liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,888&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,942&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Long-term operating lease liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,191&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,755&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Deferred income taxes, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,606&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,622&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Other long-term liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,845&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,202&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,348&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,303&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">806,521&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,913&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities and stockholders' equity</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">913,869&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">787,216&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ADJUSTED FINANCIAL MEASURES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Unaudited, in thousands, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.649%"><tr><td style="width:1.0%"></td><td style="width:66.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.663%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.619%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #333333;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #333333;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #333333;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income from continuing operations</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,139&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,614&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Share-based compensation expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,334&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,931&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-cash interest expense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">    </font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Amortization related to acquisitions and intangible assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,186&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,539&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Amortization of financial royalty assets </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,262&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(493)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Change in contingent liabilities </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(671)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Novan operating loss</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,160&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Gain from short-term investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110,772)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39,533)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Realized gain from short-term investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,979&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,552&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Provision for current expected credit losses on financial royalty assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,841)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Loss from equity method investment in Primrose Bio</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,352&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Income tax effect of adjusted reconciling items above</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,197&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,980&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Excess tax benefit (shortfall) from share-based compensation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">465&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(212)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted net income from continuing operations</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,665&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,904&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains from sales of VKTX stock, net of tax</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47,857)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,548)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Core adjusted net income from continuing operations</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,808&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,356&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted per-share amounts attributable to common shareholders&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted net income per share from continuing operations</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.75&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.43&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Share-based compensation expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.40&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.34&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-cash interest expense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Amortization related to acquisitions and intangible assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.45&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.49&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Amortization of financial royalty assets </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.03)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Change in contingent liabilities </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.04)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Novan operating loss</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.34&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Gain from short-term investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.11)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.26)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Realized gain from short-term investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.31&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Provision for current expected credit losses on financial royalty assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Loss from equity method investment in Primrose Bio</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.13&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other </font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Income tax effect of adjusted reconciling items above</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.51&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.09&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Excess tax benefit (shortfall) from share-based compensation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.03&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.01)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Adjustment for shares excluded using the if-converted method under ASU 2020-06 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.07&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted diluted net income per share from continuing operations</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.84&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.28&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains from sales of VKTX stock, net of tax</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.64)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.95)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Core adjusted diluted net income per share from continuing operations</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.20&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.33&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP - weighted average number of common shares - diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,122&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,974&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Diluted effect of the 2023 Notes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(483)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted weighted average number of common shares - diluted</font></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,122&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,491&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)  Amounts represent non-cash debt related costs that are calculated in accordance with the authoritative accounting guidance for our revolving credit facility and convertible debt instruments that may be settled in cash.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Amounts represent the adjustments bridging the income from financial royalty assets to total contractual payments recorded in the period.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)  Amounts represent changes in fair value of contingent consideration related to CyDex and Metabasis transactions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Excess tax benefits from share-based compensation are recorded as a discrete item within the provision for income taxes on the consolidated statements of operations as a result of the adoption of an accounting pronouncement (ASU 2016-09) on January 1, 2017. Prior to the adoption, the amount was recognized in additional paid-in capital on the consolidated statement of stockholders' equity.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5) Q1 2023 numbers are adjusted to exclude after-tax impact from realized gain of Viking common stock. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6) Excluding the impact from the adoption of accounting pronouncement (ASU 2020-06) on January 1, 2022 as the Company intended to settle the principal balance in cash. Under the standard, the Company is required to reflect the dilutive effect of the 2023 Notes by application of the if-converted method.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"># # #</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lgnd-20240507.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:e19915be-7a7d-4a0a-a910-a91be24fe392,g:99d91fad-30df-4421-95f8-e2e75b059fe5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lgnd="http://www.ligand.com/20240507" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ligand.com/20240507">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20240507_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20240507_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.ligand.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>lgnd-20240507_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:e19915be-7a7d-4a0a-a910-a91be24fe392,g:99d91fad-30df-4421-95f8-e2e75b059fe5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_78afbc3f-7113-4e07-85ed-4a95acab2933_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_65b8e563-341e-4db7-b107-f1e81ea50e6e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_bd2f39b4-f777-4298-9210-705a6dfc1efc_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ce823d68-2e9a-4856-b4ff-89cb8874b482_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b2ede182-e126-4664-a6d7-b52a58ca4c7a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ff085f49-11ed-49fa-9427-959a9684eacd_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_04420270-56e8-4d07-938e-15375cfa3887_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_d608afed-d019-4782-94e1-8eb0189ddd5a_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_25c0a91e-67c5-4c9f-be80-bbdeae169186_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_cc57c1e7-6cc0-4bee-a90e-34b8c49ff6f3_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6f8de322-3015-4d16-95fd-08d838ff2e80_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_2eec477c-fbac-48f5-9965-0923b968a8b1_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_5e0c7fa7-683d-4060-94e1-a3e721293033_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ebe0100a-f35c-47e3-976f-9383823188eb_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_913d3041-b539-4846-80df-434da7edf702_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_037ff72e-2df6-47d4-b59b-bcd35a30bc44_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_84f6ad1e-7400-4825-9830-70adf062bc08_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_29a12e61-946b-47af-bae1-166d69798574_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_edff1d18-6c5f-4a5d-b2ae-02f5dd2fc69e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_df42089b-c6ce-49b5-be53-4a016c1d9c14_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1d97baa6-3b31-4620-bc52-57f1f773d1ee_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_68cbf9c5-a445-4a3e-a388-009a0e87b6d5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a0d4c846-b70e-4538-8ced-e3a79b45a999_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>lgnd-20240507_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:e19915be-7a7d-4a0a-a910-a91be24fe392,g:99d91fad-30df-4421-95f8-e2e75b059fe5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ligand.com/role/CoverPage" xlink:type="simple" xlink:href="lgnd-20240507.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_260b822f-8fcc-4f1e-983e-fbc01ff1d535" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_EntityCentralIndexKey_260b822f-8fcc-4f1e-983e-fbc01ff1d535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4958bee6-733b-480b-8607-b8767ff8a904" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_AmendmentFlag_4958bee6-733b-480b-8607-b8767ff8a904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_27b6313f-40dc-4bc0-bd17-a5a022304f05" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_DocumentType_27b6313f-40dc-4bc0-bd17-a5a022304f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8c9814cc-ad84-4529-bc93-83991a98bcc1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_DocumentPeriodEndDate_8c9814cc-ad84-4529-bc93-83991a98bcc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d882e0c5-3419-4c30-a466-997752806797" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_EntityRegistrantName_d882e0c5-3419-4c30-a466-997752806797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_04cec8e7-79a8-47b3-8029-f6b3024e3e76" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_04cec8e7-79a8-47b3-8029-f6b3024e3e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_42351da3-848b-4b45-be7c-3b58e5113d37" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_EntityFileNumber_42351da3-848b-4b45-be7c-3b58e5113d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c077497a-27b4-41f4-bde0-763b6fcf72b7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_EntityTaxIdentificationNumber_c077497a-27b4-41f4-bde0-763b6fcf72b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_51e74e33-039a-45b9-9020-3409932058c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_EntityAddressAddressLine1_51e74e33-039a-45b9-9020-3409932058c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4a4796cc-f0fe-4bfc-be25-cc6344262041" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_EntityAddressCityOrTown_4a4796cc-f0fe-4bfc-be25-cc6344262041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_26081194-ca00-4365-a2ba-a3c032e996ef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_EntityAddressStateOrProvince_26081194-ca00-4365-a2ba-a3c032e996ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a41f8992-9a70-466d-833c-89bfd17fafbe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_EntityAddressPostalZipCode_a41f8992-9a70-466d-833c-89bfd17fafbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d6b827fb-ab86-483b-8641-e84aa31180fc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_CityAreaCode_d6b827fb-ab86-483b-8641-e84aa31180fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6c130b49-886c-4689-999c-a9a180d282f4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_LocalPhoneNumber_6c130b49-886c-4689-999c-a9a180d282f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_8b5aaa99-c1f7-450f-8072-346777ae3511" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_WrittenCommunications_8b5aaa99-c1f7-450f-8072-346777ae3511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_4c7e766d-5be8-47ea-bcf3-da933714bab0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_SolicitingMaterial_4c7e766d-5be8-47ea-bcf3-da933714bab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_b93ab7b2-bc3b-435e-bd2e-59f0b74208fa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_PreCommencementTenderOffer_b93ab7b2-bc3b-435e-bd2e-59f0b74208fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_9ec3cc6a-8861-4359-83ae-296da3308dd4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_9ec3cc6a-8861-4359-83ae-296da3308dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_dcc6822b-387a-473b-91d1-3065ded26d30" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_Security12bTitle_dcc6822b-387a-473b-91d1-3065ded26d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_bd852ff5-88c7-4193-adf6-4cc582fa47c0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_TradingSymbol_bd852ff5-88c7-4193-adf6-4cc582fa47c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d193ee11-0510-4254-894a-fd19051c77cd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_SecurityExchangeName_d193ee11-0510-4254-894a-fd19051c77cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2fdc7b70-bf36-40f5-81f8-2fba96f49f2e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e20b2bd6-ea42-458e-a25f-add27d0dbe1a" xlink:to="loc_dei_EntityEmergingGrowthCompany_2fdc7b70-bf36-40f5-81f8-2fba96f49f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>newligandlogo.jpg
<TEXT>
begin 644 newligandlogo.jpg
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MY5A7QP8   " E:*W^E0SI?/VV(HQ      Y+,08   ! 2XHQ     %I2C $
M  #0DF(,    @)848P    "TI!@#    H"7%&      M*<8     :$DQ!@
M $!+BC$     6E*, 0   -"28@P   " EA1C     +2D& ,   "@)<48
M "TIQ@    !H23$&    0$N*,0    !:4HP!    T))B#    ("6%&,
MM*08 P   * EQ1@     +2G&     &A),08   ! 2XHQ     %I2C $   #0
MDF(,    @)848P    "TI!@#    H"7%&      M*<8     :$DQ!@   $!+
MBC$     6E*, 0   -"28@P   " EA1C     +2D& ,   "@)<48     "TI
MQ@    !H23$&    0$N*,0    !:4HP!    T))B#    ("6%&,     M*08
M P   * EQ1@     +2G&     &A),08   ! 2XHQ     %I2C $   #0DF(,
M    @)848P    "TI!@#    H"7%&      M*<8     :$DQ!@   $!+BC$
M    6E*, 0   -"28@P   " EA1C     +2D& ,   "@)<48     "TIQ@
M  !H23$&    0$N*,0    !:4HP!    T))B#    ("6%&,     M*08 P
M * EQ1@     +2G&     &A),08   ! 2XHQ     %I2C $   #0DF(,
M@)848P    "TI!@#    H"7%&      M*<8     :$DQ!@   $!+BC$
M6E*, 0   -"28@P   " EA1C     +2D& ,   "@)<48     "TIQ@    !H
M23$&    0$N*,0    !:4HP!    T))B#    ("6%&,     M*08 P   * E
MQ1@     +2G&     &A),08   ! 2XHQ     %I2C $   #0DF(,    @)84
M8P    "TI!@#    H"7%&      M*<8     :$DQ!@   $!+BC$     6E*,
M 0   -"28@P   " EA1C     +2D& ,   "@)<48     "TIQ@    !H23$&
M    0$N*,0    !:4HP!    T))B#    ("6%&,     M*08 P   * EQ1@
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M     "TIQ@    !H23$&    0$N*,0    !:4HP!    T))B#    ("6%&,
M    M*08 P   * EQ1@     +2G&     &A),08   ! 2XHQ     %I2C $
M  #0DF(,    @)848P    "TI!@#    H"7%&      M*<8     :$DQ!@
M $!+BC$     6E*, 0   -"28@P   " EA1C     +2D& ,   "@)<48
M "TIQ@    !H23$&    0$N*,0    !:4HP!    T))B#    ("6%&,
MM*08 P   * EQ1@     +2G&     &A),08   ! 2XHQ     %I2C $   #0
MDF(,    @)848P    "TI!@#    H"7%&      M*<8     :$DQ!@   $!+
MBC$     6E*, 0   -"28@P   " EA1C     +2D& ,   "@)<48     "TI
MQ@    !H23$&    0$N*,0    !:4HP!    T))B#    ("6%&,     M*08
M P   * EQ1@     +2G&     &A),08   ! 2XHQ     %I2C $   #0DF(,
M    @)848P    "TI!@#    H"7%&      M*<8     :$DQ!@   $!+BC$
M    6E*, 0   -"28@P   " EA1C     +2D& ,   "@)<48     "TIQ@
M  !H23$&    0$N*,0    !:4HP!    T))B#    ("6%&,     M*08 P
M * EQ1@     +2G&     &A),08   ! 2XHQ     %I2C $   #0DF(,
M@)848P    "TI!@#    H"7%&      M*<8     :$DQ!@   $!+BC$
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MTB)7_=<+Q9B(B(B(B(B(B+3(5?_U8ER,_?FO_GO\?P     PBS?]UX?%&
M  !,33$&    0$N*,0    !:^K$8^^G/?_F+V' ?     +KXDY__\L_^/P3@
2YQ5 G(I#     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139811024625872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>May 07, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000886163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  07,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIGAND PHARMACEUTICALS INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0160744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">555 Heritage Drive, Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Jupiter<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">550-7500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LGND<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M'AI:)OF)<R4UG%_SRRVCL!;,"_!\+:7^:)A#;/$_B,$_4$L#!!0    ( &R
MIUB?H!OPL0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB
M:N*1&+9 8;"-0O-A7Y58=@1Z\62Y<_KKI[-L)VEU9=V'L<VAR=T]NKM'=R>9
MKEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R
M6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8
MRY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%
ME#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"
M3J9B+7D%=*RHC_#K3), Z)Q17B@%JXUF X?)8Q1\V .7\@%:^*VZBMU7)/3B
M4PEM(+#52?2$1C&$"0K$OXP68E^$O?VML*01C\9][/QN]*!_[XSC]Y97HA_T
MOIKS8]$7>'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY
M85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$
M&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*
M3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?
M@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S
M/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM
M%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&89
M4IT,/O'^8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$
M4$L#!!0    ( &R IUB7BKL<P    !,"   +    7W)E;',O+G)E;'.=DKEN
MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " !L@*=8!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( &R IUB'L<_E[P   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( &R IUB97)PC$ 8  )PG   3
M          "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M;("G6&7AU7U8!   CQ   !@              ("!#@@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( &R IUB?H!OPL0(  .(,   -
M          "  9P,  !X;"]S='EL97,N>&UL4$L! A0#%     @ ;("G6)>*
MNQS     $P(   L              ( !> \  %]R96QS+RYR96QS4$L! A0#
M%     @ ;("G6!E%%?4W 0  )P(   \              ( !81   'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( &R IU@D'INBK0   /@!   :
M      "  <41  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( &R IUAED'F2&0$  ,\#   3              "  :H2  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /03      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lgnd-20240507.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="lgnd-20240507.htm">lgnd-20240507.htm</File>
    <File>lgnd-20240507.xsd</File>
    <File>lgnd-20240507_lab.xml</File>
    <File>lgnd-20240507_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lgnd-20240507.htm": {
   "nsprefix": "lgnd",
   "nsuri": "http://www.ligand.com/20240507",
   "dts": {
    "inline": {
     "local": [
      "lgnd-20240507.htm"
     ]
    },
    "schema": {
     "local": [
      "lgnd-20240507.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "lgnd-20240507_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lgnd-20240507_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.ligand.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20240507.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20240507.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover page.",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000886163-24-000029-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000886163-24-000029-xbrl.zip
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MFJGO6$4^&'RQH"LAPV-N>CC44<L9M@)RZ$;LSA*M.]X[@23Y'.%G$R$BHP
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M^*SQ?F!,OMXX7-C1^'B_>"+E.38<'SP<:#_:U^*/#_X'4$L#!!0    ( &R
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M:/#QD#N3 %XL77JQ^"$#DOQT7>$*PD193]^UG @,0_9- .MQC9D$I*T#!)A
M]F&J/I(>I?0,F.Q[<OF;:38-!B;)$-=%D8"&UA/ K3!'D$(@Z^71U\]=1B"#
MG_\]<H4!\QJ7:$7ADX%@-;S.@4#LAG\7=CJ$P /X=@ 4>&C ?,;"0H"$UR@T
ME+X=2Y!"/OQU1AH<#BA#P_O/\>GUUV]G)__XV6S5#^!F-HJL8<D5 G$R1%N9
M5A61=N0Y3@1H-2*^Y /I!1%0'KY*BTD$C'E\'J:>J6JG#4$P9P^V1OD^RQ3;
MBGDMQNH;+R2T!9 %_4-\I, 9Y,,#[15KWS[-/X/81 +06X+]4C/+%09C R%S
M#63!,>"^K4#BEWH]O9B\+> C G/IV5HL:V68#0(.(MHJ'S4[9?/>CYJM<G.5
MCQKJ?KP*\_5140&*2E@OH#3H=1#_7A3RGD/HW!T!XB7B.65'=<^^G.^S/R8
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MJW\$%^VA$*0JCQJ\U(>4-/%F,ZNCX?Y?ZN56 RD)F.=$:,X&H"/%["JX*PT
M/O5+O9:J"_6%:KE>6_2%I6MYDS4 X+>S Y@!R?CQ@"0X-1C(Q845_!L^.^ 8
MKZ*G@R'(< E=&'CI+: X"D^ 7H('YF,8S_J;_(XSG(+P*<W[[0]4XJ $P%+
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M*W3^,R'V[V*225'&84U*6E,NNYS:E8$JX BUDE-Z W_';9N\1Q3=:36?1G"
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MHH\H 8-E+P-2/%)I.XFY!W392Z%74JZ[7@B5X*5,VP@,CSBR1*CKJ?@\?!R
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M@9'T/-H6ABZ*#46<M\>^D[B>2\@7[[5=0F"=45.ME5!QTE8.;8UG[@./&=X
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M N%7FO :";?4\WE--;,R56LQ55_T\XWR@V8'#&"!C8P4+U7+[7EEU>.!P!>
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MCG]8 IP;1)>><$5?AFR/@K)][CC[<9#VGIUD.U@;4\]S;4R]6;3]7TLLS=Q
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M,#(T,#4P-RYX<V102P$"% ,4    " !L@*=8UPGR R@*  !X50  %0
M        @ %E$@  ;&=N9"TR,#(T,#4P-U]L86(N>&UL4$L! A0#%     @
M;("G6.(,[>&P!@  YC   !4              ( !P!P  &QG;F0M,C R-# U
M,#=?<')E+GAM;%!+ 0(4 Q0    ( &R IUC.KY(8]C<  )B* @ ?
M      "  :,C  !Q,3(P,C1E87)N:6YG<W)E;&5A<V5?97@Y.3$N:'1M4$L%
3!@     %  4 40$  -9;      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>lgnd-20240507_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lgnd-20240507.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2024-05-07</startDate>
            <endDate>2024-05-07</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0000886163</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-05-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">LIGAND PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-33093</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">77-0160744</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">555 Heritage Drive, Suite 200</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Jupiter</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">33458</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">550-7500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">LGND</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
